Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Elcubragistat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL known ✓ | Q99685 | 18/20 | 0.98 |
| ▸ | ABHD6 | Q9BV23 | 17/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | PLA2G7 | Q13093 | 11/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elcubragistat SCHEMBL29430972 | 1.00 | MGLL (0.98) | MGLLABHD6CYP2D6PLA2G7 | |
| Elcubragistat SCHEMBL20168257 | 1.00 | MGLL (0.98) | MGLLABHD6CYP2D6PLA2G7 | |
| Elcubragistat SCHEMBL29430943 | 1.00 | MGLL (0.98) | MGLLABHD6CYP2D6PLA2G7 | |
| Elcubragistat SCHEMBL15100632 | 0.99 | MGLL (1.00) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL23349060 | 0.98 | MGLL (1.00) | MGLLABHD6CYP2D6PLA2G7 | |
| Elcubragistat SCHEMBL29430992 | 0.93 | MGLL (0.89) | MGLLABHD6CYP2D6PLA2G7 | |
| Elcubragistat SCHEMBL29430963 | 0.93 | MGLL (0.89) | MGLLABHD6CYP2D6PLA2G7 | |
| Elcubragistat SCHEMBL20168245 | 0.93 | MGLL (0.89) | MGLLABHD6CYP2D6PLA2G7 | |
| Elcubragistat SCHEMBL20167123 | 0.93 | MGLL (0.89) | MGLLABHD6CYP2D6PLA2G7 | |
| Elcubragistat SCHEMBL20167125 | 0.93 | MGLL (0.89) | MGLLABHD6CYP2D6PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993588-B2 | Crystalline forms of a MAGL inhibitor | H. LUNDBECK A/S (DK) | 2024-05-28 | — | — | US | claimed |
| US-20240158360-A1 | Synthesis of a Monoacylglycerol Lipase Inhibitor | H. LUNDBECK A/S (DK) | 2024-05-16 | — | — | US | claimed |
| US-11702393-B2 | Synthesis of a monoacylglycerol lipase inhibitor | H. LUNDBECK A/S (DK) | 2023-07-18 | — | — | US | claimed |
| EP-4139288-A1 | SYNTHESIS OF A MONOACYLGLYCEROL LIPASE INHIBITOR | H. Lundbeck A/S (DK) | 2023-03-01 | — | — | EP | claimed |
| CN-115427403-A | Synthesis of monoacylglycerol lipase inhibitors | H.隆德贝克有限公司 | 2022-12-02 | — | — | CN | claimed |
| US-20220235037-A1 | CRYSTALLINE FORMS OF A MAGL INHIBITOR | H. LUNDBECK A/S (DK) | 2022-07-28 | — | — | US | claimed |
| US-11273159-B2 | Pharmaceutical formulations | H. LUNDBECK A/S (DK) | 2022-03-15 | — | — | US | claimed |
| WO-2021214550-A1 | SYNTHESIS OF A MONOACYLGLYCEROL LIPASE INHIBITOR | H. LUNDBECK A/S (DK) | 2021-10-28 | — | — | WO | claimed |
| US-20210323938-A1 | Synthesis of a Monoacylglycerol Lipase Inhibitor | H. LUNDBECK A/S (DK) | 2021-10-21 | — | — | US | claimed |
| US-11142517-B2 | Crystalline forms of a MAGL inhibitor | H. LUNDBECK A/S (DK) | 2021-10-12 | — | — | US | claimed |
| US-20200190063-A1 | CRYSTALLINE FORMS OF A MAGL INHIBITOR | H. LUNDBECK A/S (DK) | 2020-06-18 | — | — | US | claimed |
| US-20200188393-A1 | PHARMACEUTICAL FORMLATIONS | H. LUNDBECK A/S (DK) | 2020-06-18 | — | — | US | claimed |
| EP-3541807-A1 | CRYSTALLINE FORMS OF A MAGL INHIBITOR | Abide Therapeutics, Inc. (US) | 2019-09-25 | — | — | EP | claimed |
| EP-3541385-A1 | PHARMACEUTICAL FORMULATIONS | Abide Therapeutics, Inc. (US) | 2019-09-25 | — | — | EP | claimed |
| WO-2018093950-A1 | PHARMACEUTICAL FORMULATIONS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | claimed |
| WO-2018093953-A1 | CRYSTALLINE FORMS OF A MAGL INHIBITOR | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | claimed |
| US-11993588-B2 | Crystalline forms of a MAGL inhibitor | H. LUNDBECK A/S (DK) | 2024-05-28 | — | — | US | disclosed |
| US-20240158360-A1 | Synthesis of a Monoacylglycerol Lipase Inhibitor | H. LUNDBECK A/S (DK) | 2024-05-16 | — | — | US | disclosed |
| WO-2018093953-A1 | CRYSTALLINE FORMS OF A MAGL INHIBITOR | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093950-A1 | PHARMACEUTICAL FORMULATIONS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11142517-B2 | Crystalline forms of a MAGL inhibitor | MAG, MAGI3, PYM1 | MGLL 5/4885ABHD6 462/4885CYP2D6 4164/4885 |
| US-20240158360-A1 | Synthesis of a Monoacylglycerol Lipase Inhibitor | MGLL, PNLIP, LPL | MGLL 1/4885ABHD6 20/4885CYP2D6 2943/4885 |
| US-20220235037-A1 | CRYSTALLINE FORMS OF A MAGL INHIBITOR | MAG, MAGI3, PYM1 | MGLL 5/4885ABHD6 462/4885CYP2D6 4164/4885 |
| US-20200190063-A1 | CRYSTALLINE FORMS OF A MAGL INHIBITOR | MAG, MAGI3, PYM1 | MGLL 5/4885ABHD6 462/4885CYP2D6 4164/4885 |
| US-11993588-B2 | Crystalline forms of a MAGL inhibitor | MAG, MAGI3, PYM1 | MGLL 5/4885ABHD6 462/4885CYP2D6 4164/4885 |
| US-20200188393-A1 | PHARMACEUTICAL FORMLATIONS | MGLL, LIPA, CEL | MGLL 1/4885ABHD6 39/4885CYP2D6 639/4885 |
| US-11273159-B2 | Pharmaceutical formulations | MGLL, LIPA, PNLIP | MGLL 1/4885ABHD6 20/4885CYP2D6 1009/4885 |
| US-20210323938-A1 | Synthesis of a Monoacylglycerol Lipase Inhibitor | MGLL, PNLIP, LPL | MGLL 1/4885ABHD6 20/4885CYP2D6 2943/4885 |
| US-11702393-B2 | Synthesis of a monoacylglycerol lipase inhibitor | MGLL, PNLIP, LPL | MGLL 1/4885ABHD6 20/4885CYP2D6 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.